CL2020002225A1 - Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal - Google Patents

Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal

Info

Publication number
CL2020002225A1
CL2020002225A1 CL2020002225A CL2020002225A CL2020002225A1 CL 2020002225 A1 CL2020002225 A1 CL 2020002225A1 CL 2020002225 A CL2020002225 A CL 2020002225A CL 2020002225 A CL2020002225 A CL 2020002225A CL 2020002225 A1 CL2020002225 A1 CL 2020002225A1
Authority
CL
Chile
Prior art keywords
treatment
antibodies
inflammatory bowel
bowel disease
ibd
Prior art date
Application number
CL2020002225A
Other languages
English (en)
Inventor
Wulf Otto Boecher
Janine Lamar
Steven John Padula
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2020002225A1 publication Critical patent/CL2020002225A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al tratamiento de la enfermedad inflamatoria intestinal (IBD) con anticuerpos anti-IL36R.
CL2020002225A 2018-03-14 2020-08-28 Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal CL2020002225A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642641P 2018-03-14 2018-03-14
US201862729511P 2018-09-11 2018-09-11
US201862743778P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
CL2020002225A1 true CL2020002225A1 (es) 2021-01-22

Family

ID=65995838

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002225A CL2020002225A1 (es) 2018-03-14 2020-08-28 Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal

Country Status (13)

Country Link
US (3) US20190284273A1 (es)
EP (2) EP3765515A2 (es)
JP (1) JP2021517577A (es)
KR (1) KR20200131303A (es)
CN (1) CN111868090A (es)
AU (1) AU2019234478A1 (es)
BR (1) BR112020016401A2 (es)
CA (1) CA3090421A1 (es)
CL (1) CL2020002225A1 (es)
IL (1) IL277217A (es)
MX (1) MX2020009540A (es)
PH (1) PH12020551443A1 (es)
WO (1) WO2019177883A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745898C2 (ru) 2015-04-15 2021-04-02 Анаптисбайо, Инк. Антитела, направленные против рецептора интерлейкина 36 (il-36r)
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
WO2019177883A2 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
IL280013B2 (en) 2018-07-16 2026-05-01 Regeneron Pharmaceuticals Inc Anti-IL36R antibodies
EA202192405A1 (ru) * 2019-03-08 2022-01-13 Бёрингер Ингельхайм Интернациональ Гмбх Составы антител против il-36r
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
JP2023536851A (ja) 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
WO2022212510A1 (en) * 2021-04-01 2022-10-06 Medibeacon Inc. Methods of monitoring mucosal healing
US20230049147A1 (en) * 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
RS67639B1 (sr) 2011-11-16 2026-02-27 Boehringer Ingelheim Int Anti il-36r antitela
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
RU2745898C2 (ru) * 2015-04-15 2021-04-02 Анаптисбайо, Инк. Антитела, направленные против рецептора интерлейкина 36 (il-36r)
DK3285831T3 (da) 2015-04-24 2024-05-27 Shl Medical Ag Underenhed af en medikamenttilførselsanordning og en medikamenttilførselsanordning
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
US20180273627A1 (en) * 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
WO2019177883A2 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
EA202192405A1 (ru) * 2019-03-08 2022-01-13 Бёрингер Ингельхайм Интернациональ Гмбх Составы антител против il-36r

Also Published As

Publication number Publication date
KR20200131303A (ko) 2020-11-23
US20240018232A1 (en) 2024-01-18
IL277217A (en) 2020-10-29
JP2021517577A (ja) 2021-07-26
AU2019234478A1 (en) 2020-08-20
WO2019177883A2 (en) 2019-09-19
PH12020551443A1 (en) 2021-08-23
US20210061901A1 (en) 2021-03-04
WO2019177883A3 (en) 2020-03-26
US20190284273A1 (en) 2019-09-19
BR112020016401A2 (pt) 2020-12-15
EP3765515A2 (en) 2021-01-20
CA3090421A1 (en) 2019-09-19
CN111868090A (zh) 2020-10-30
MX2020009540A (es) 2020-10-05
EP4183804A1 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
PH12020551443A1 (en) Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
DOP2018000010A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
CO2017012974A2 (es) Anticuerpos de unión a tau
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
EA201591285A1 (ru) Иммунотерапия тау
EA201691541A1 (ru) Новые анти-baff антитела
CL2017001090A1 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
MX2018007288A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
CO2017012971A2 (es) Anticuerpos de unión a tau
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
UA123202C2 (uk) Антитіло до тау-білка і його застосування
CL2019003557A1 (es) Anticuerpos anti-trkb.
EA201790879A1 (ru) 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
MX2024012972A (es) Vedolizumab para el tratamiento de pacientes pediatricos
EA201790885A1 (ru) 6α-АЛКИЛ-6,7-ДИОНОВЫЕ СТЕРОИДЫ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ ДЛЯ ПОЛУЧЕНИЯ СТЕРОИДНЫХ МОДУЛЯТОРОВ FXR